KBC Group’s Ascendis Pharma A/S ASND Stock Holding History

KBC Group’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$10K	Sell	44 -234	-84%	-$59.3K	﹤0.01%	1820
2026 Q2	$74K	Sell	278 -78	-22%	-$18.2K	﹤0.01%	1566
2026 Q1	$81K	Hold	356	–	–	﹤0.01%	1445
2025 Q4	$76K	Hold	356	–	–	﹤0.01%	1457
2025 Q3	$71K	Hold	356	–	–	﹤0.01%	1478
2025 Q2	$61K	Sell	356 -55	-13%	-$8.96K	﹤0.01%	1492
2025 Q1	$64K	Hold	411	–	–	﹤0.01%	1712
2024 Q4	$57K	Hold	411	–	–	﹤0.01%	1789
2024 Q3	$61K	Buy	+411	New	+$55.5K	﹤0.01%	1618

Other funds holding ASND

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

ARS Investment Partners New York $2.23B AUM 74.02% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $25.3B AUM 15.9% 1-Year Est. Return

Braun Stacey Associates New York $3.48B AUM 48.73% 1-Year Est. Return

Sapient Capital Indianapolis, Indiana $7.44B AUM 23.27% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return

KBC Group's ASND Position: Q3 2026 in Review

KBC Group reduced its Ascendis Pharma A/S (ASND) stake by 84% in Q3 2026, selling an estimated $59.3K and leaving 44 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #1820.

KBC Group first reported a position in ASND in Q3 2024 and has held it in 9 quarters since. The position peaked at $81K in Q1 2026. 132 funds tracked by Wall St. Rank hold ASND as of Q3 2026.

KBC Group held 44 shares of Ascendis Pharma A/S worth $10K as of Q3 2026.
KBC Group sold 234 Ascendis Pharma A/S shares in Q3 2026, an estimated $59.3K.
Ascendis Pharma A/S made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1820 holding.
KBC Group first reported a position in Ascendis Pharma A/S in Q3 2024 and has held it in 9 quarters since.
KBC Group's Ascendis Pharma A/S position peaked at $81K in Q1 2026.
132 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.